Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

PHASE3RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

November 30, 2026

Conditions
Pre-Bronchiolitis Obliterans Syndrome
Interventions
DRUG

ARINA-1

ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)

OTHER

Standard of care only

Standard 3-therapy immunosuppression regimen and azithromycin

Trial Locations (16)

10032

RECRUITING

Columbia University Irving Medical Center, New York

21287

RECRUITING

Johns Hopkins Hospital, Baltimore

29452

RECRUITING

Medical University of South Carolina, Charleston

32803

RECRUITING

Advent Health, Orlando

33606

RECRUITING

University of South Florida, Tampa

43221

RECRUITING

The Ohio State University Wexner Medical Center, Columbus

44195

RECRUITING

Cleveland Clinic, Cleveland

45390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

52242

RECRUITING

University of Iowa Hospital, Iowa City

55455

RECRUITING

University of Minnesota Medical School, Minneapolis

63110

RECRUITING

Washington University School of Medicine, St Louis

75246

RECRUITING

Baylor Scott and White Research Institute, Dallas

77030

RECRUITING

Houston Methodist Hospital, Houston

85013

WITHDRAWN

Dignity Health - St. Joseph's Hospital and Medical Center, Phoenix

90095

RECRUITING

University of California Los Angeles School of Medicine, Los Angeles

92103

RECRUITING

University of California San Diego Health, San Diego

All Listed Sponsors
lead

Renovion, Inc.

INDUSTRY